Search

Displaying results 3221 - 3230 of 7607 in total
  1. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.

  2. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite … These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin.

  3. Drug

    Perphenazine

    go.drugbank.com/drugs/DB00850
    ApprovedInvestigational

    An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

  4. Drug

    Clobetasone

    go.drugbank.com/drugs/DB13158
    Approved

    Clobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions. Topical clobetasone butyr...

    Products: U-CLOSONE CREAM, U-CLOSONE OINTMENT
  5. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection. … This makes it useful for some types of pain that don't respond well to other opioids.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Cytisine

    go.drugbank.com/drugs/DB09028
    Investigational

    Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost. … Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy.

  7. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    by H. pylori. … Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion

  8. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S. … [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.

  9. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels.

  10. Drug

    Bumadizone

    go.drugbank.com/drugs/DB13286
    Approved

    Its use is restricted to these conditions, due to risks this drug poses [L5650].

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS